文献速递肺外科

脂质体布比卡因肋间神经阻滞对减少肺部并发症的重要性

Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications.
PubMed 文献 · Ann Thorac Surg · 2020-10-28

该单中心回顾性研究纳入2006至2017年2865例I至III期非小细胞肺癌肺切除患者,其中860例(30%)接受脂质体布比卡因后肋间神经阻滞。逻辑回归显示脂质体布比卡因与肺部并发症减少相关(OR 0.63;

要点

  • 脂质体布比卡因后肋间神经阻滞与肺切除后主要肺部并发症减少独立相关。
  • 该获益是在加速康复外科(ERAS)积极实施背景下观察到的。
  • 作者建议各医院根据自身情况评估该技术的应用。

核心结论

  • 作为积极加速康复方案的一部分,脂质体布比卡因与主要肺部并发症减少相关,其应用应逐院评估。

研究设计与样本

  • 单中心回顾性队列研究,纳入2006至2017年因I至III期非小细胞肺癌行肺切除的患者2865例。

主要发现

  • 主要肺部并发症(肺炎、急性呼吸窘迫综合征、呼吸骤停、再插管、支气管镜或带氧出院)发生于455例(16%)。
  • 860例(30%)接受脂质体布比卡因后肋间神经阻滞,该技术自2012年起逐步采用至2017年全面开展。
  • 与肺部并发症发生相关的其他因素包括年龄、体重指数、吸烟、肺功能值及术中失血量。

临床怎么用

  • 在加速康复外科路径中可考虑采用脂质体布比卡因后肋间神经阻滞以降低肺切除后肺部并发症风险。
  • 应结合本院实际评估该技术的适用性与实施效果。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和未测量混杂因素。
  • 原文未报告具体的混杂因素调整细节及脂质体布比卡因给药方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We have previously demonstrated that Enhanced Recovery After Surgery protocols are associated with a reduction in pulmonary complications. As a component of enhanced recovery pathways, intercostal nerve blocks with liposomal bupivacaine are increasingly utilized, but the extent to which this element may contribute to such outcomes has not been evaluated. METHODS: Patients undergoing lung resection for stage I to III non-small cell lung cancer at a single institution from 2006 to 2017 were examined for major postoperative pulmonary morbidity, defined as pneumonia, acute respiratory distress syndrome, respiratory arrest, reintubation, bronchoscopy, or need for discharge with oxygen. Pharmacy records were queried for administration of liposomal bupivacaine via posterior intercostal nerve block. Patients treated with and without liposomal bupivacaine were compared in a logistic regression to determine the impact on pulmonary morbidity. RESULTS: A total of 2865 patients were identified, including 860 (30%) who were treated with liposomal bupivacaine via posterior intercostal block. Pulmonary morbidity occurred in 455 (16%). Adoption of liposomal bupivacaine analgesia occurred over several years, beginning in 2012 to full adoption by 2017. Liposomal bupivacaine management was associated with a reduction in pulmonary complications, as compared with nonuse (odds ratio, 0.63; P = .006). Additional factors associated with the occurrence of pulmonary morbidity were age, body mass index, smoking, spirometry values, and operative blood loss. CONCLUSIONS: As a component of an active enhanced recovery program, liposomal bupivacaine is associated with a reduction in major pulmonary complications, and utilization should be evaluated on a hospital-by-hospital basis.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Corsini EM, Mitchell KG, Zhou N, et al. Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. Ann Thorac Surg. 2020. PMID: 33129774. doi:10.1016/j.athoracsur.2020.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。